PTPN6 and cancer: Previous studies demonstrated an enhanced capacity for motheaten F5 TCR transgenic T cells compared to control F5 T cells to control the growth of B16-NP68 tumours in ACT experiments [71], further adding to the evidence for a negative regulatory function of PTPN6 in the control of T cell anti-cancer responses.